Erratum for Ikeda et al., “Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease”

概要

Erratum

Yonago Acta Medica 2020;63(4):385 doi: 10.33160/yam.2020.11.011

Erratum for Ikeda et al., “Pemafibrate Dramatically Ameliorated the Values of Liver
Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver
Disease”
Suguru Ikeda,* Takaaki Sugihara,* Yoshiki Hoshino,* Yukako Matsuki,* Takakazu Nagahara,* Jun-ichi Okano,*
Sonoko Kitao,† Youhei Fujioka,† Kazuhiro Yamamoto† and Hajime Isomoto*
*Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine,
Tottori University, Yonago 683-8504, Japan and †Division of Medicine and Clinical Science, Department of Cardiovascular Medicine
and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan

ERRATUM
Yonago Acta Med. 2020;63(3):188–197 doi: 10.33160/yam.2020.08.009
There was an error in the notation of the number of administrations. The notation should be corrected as follows:
On page 191, left column, line 25
Error: Three patients (17.6%) were given 0.1 mg bid (twice-daily), twelve (70.6%), 0.2 mg bid, and two (11.8%), 0.4
mg bid of pemafibrate, respectively.
Correction: Three patients (17.6%) were given 0.1 mg qd (once-daily), twelve (70.6%), 0.1 mg bid (twice-daily), and
two (11.8%), 0.2 mg bid of pemafibrate, respectively
On page 191, right column, line 8
Error: Three biopsy-proven NASH patients were administered 0.2 mg bid of pemafibrate.
Correction: Three biopsy-proven NASH patients were administered 0.2 mg daily of pemafibrate.
On page 191, right column, line 39
Error: Fenofibrate administration needs to be at least 106.6 mg to 160 mg qd (once-daily); on the other hand, only 0.2
to 0.4 mg bid of pemafibrate is needed.
Correction: Fenofibrate administration needs to be at least 106.6 mg to 160 mg qd; on the other hand, only 0.2 to 0.4
mg daily of pemafibrate is needed.
On page 192, right column, line 2
Error: In phase 3, 58 (53.2%) subjects with fatty liver were administered 0.2 mg or 0.4 mg bid of pemafibrate;
Correction: In phase 3, 58 (53.2%) subjects with fatty liver were administered 0.2 mg or 0.4 mg daily of pemafibrate;
On page 195, right column, line 6
Error: Both were administered 0.2 mg bid.
Correction: Both were administered 0.2 mg daily.
The authors sincerely apologize for these errors and any confusion they may have caused. ...